This document does not contain any meaningful information to summarize in 3 sentences or less. It consists of random letters and symbols with no context.
20150514-Jornada tècnica Agricultura de precisió com a eina vitivinícola-JMCa...Associació AEI INNOVI
Presentació de José María Caballero de l'empresa TAMIC en la Jornada Tècnica: Agricultura de precisió com a eina vitivinícola - 14/05/2015 Vilafranca del Penedès.
"Sistemes de mesura i control per a l'agricultura"
4rt cicle tècnic d’energia a la indústria
Jornada: Granollers entre en simbiosi
Ponència: Economia circular. Casos pràctics. CEPEX
Ponent: Rosa Maria Rafecas.
This document does not contain any meaningful information to summarize in 3 sentences or less. It consists of random letters and symbols with no context.
20150514-Jornada tècnica Agricultura de precisió com a eina vitivinícola-JMCa...Associació AEI INNOVI
Presentació de José María Caballero de l'empresa TAMIC en la Jornada Tècnica: Agricultura de precisió com a eina vitivinícola - 14/05/2015 Vilafranca del Penedès.
"Sistemes de mesura i control per a l'agricultura"
4rt cicle tècnic d’energia a la indústria
Jornada: Granollers entre en simbiosi
Ponència: Economia circular. Casos pràctics. CEPEX
Ponent: Rosa Maria Rafecas.
The document provides an overview of the life sciences and healthcare sector in Catalonia's "BioRegion". It summarizes that the sector contributes 7.3% to Catalonia's GDP and includes over 1,200 companies, mainly in biotech, pharma, medtech, and digital health. Investment in startups has grown steadily over the past five years to a record €120 million in 2020. The BioRegion has strong science and technology assets, including research centers, universities, and large infrastructures conducting cutting-edge research. Future challenges include improving technology transfer, attracting and developing talent, increasing investment, and ensuring a sustainable public health system.
Biocat is the institution that brings together the life sciences and healthcare innovation community in Catalonia.
Created in 2006 at the behest of the Government of Catalonia, Biocat’s mission is to maximize the economic and social impact of the life sciences and healthcare innovation of the BioRegion.
Biocat focuses its strategy on different key points:
- Raising awareness and promoting the ecosystem, creating tools and strategies for improving the knowledge of the Catalan healthcare sector and increasing its projection both at home and abroad, with the aim of positioning the BioRegion as an international reference.
- Providing innovative training and developing talent, by designing and executing programs and initiatives to improve talent and entrepreneurship considered essential factors for the growth of the sector.
- Accelerating technology transfer and business growth by supporting and carrying out activities for increasing the value of the sector, placing special emphasis on the added value of research, knowledge and technology transfer, internationalization and access to capital.
This document discusses Catalonia's growing innovation hub status in Europe. It notes that in 2018, 17 multinationals announced new innovation set-ups in Catalonia. It also summarizes that Barcelona is ranked 34th worldwide and 8th in Europe for science output. Furthermore, the document highlights that Catalonia is currently one of the leading scientific hubs in Europe based on metrics like ERC grants and publications in Nature and Science.
Biocat has experience in accelerating healthcare projects and developing talent since 2008. In 10 years, Biocat has invested over €11 million, distributed in 300 programs attended by more than 2,300 students. By leveraging its expert, industry experienced, staff and extended network, Biocat has successfully accelerated 96 life sciences projects that generated 300 new job positions, increased the rate of successful commercialization and reduced the time to next phase. In 2013, in order to increase the impact of these strategic activities. Biocat launched Moebio, a new initiative that brings together diferent training programs to accelerate entrepreneurship and innovation in healthcare, that counts with the support of EIT Health. Moebio is ranked as one of the top accelerators in Europe according to rankings by Digitalhealth.careers, Mobile World Capital, Tech EU and HealthStartup.
Design Health Barcelona (d·HEALTH Barcelona) is a 9-month postgraduate program to develop entrepreneurs and future leaders in healthcare innovation. The course, based on the prestigious Stanford University's Biodesign Fellowship, has a needs-driven innovation focus and it guides multidisciplinary groups of students through a full cycle of innovation, from needs identification to designing and prototyping a viable solution, as well as searching for funding.
www.moebio.org
The document summarizes a report on innovation in the Catalan life sciences and healthcare sector. It finds that the sector contributes over €31 billion annually to the Catalan GDP and employs over 223,000 people. The number of life sciences companies in Catalonia grew from 968 in 2008 to over 1,000 currently, with one new company forming per week on average. Private investment in Catalan life sciences startups has increased significantly in recent years, reaching over €100 million in the first half of 2018. The report sets a vision of continuing to build on Catalonia's strengths in research and private funding to become one of the top 3 most innovative life sciences hubs in Europe by 2025.
Keynote conference during the Biocat Report 2017, by Dr. Daria Tataj, Founder of a strategy firm Tataj Innovation, and Chairwoman of the RISE High-Level Advisors to Carlos Moedas, European Commissioner for Research, Science and Innovation
Panel discussion: Being a successful healthcare entrepreneur: lessons from Boston to Barcelona, with numerous experts from CIMIT, Boston, in economics, development and strategic planning of medical devices; in prototypes and patents and founders of several startups.
EIT Health is supported by the European Institute of Innovation and Technology (EIT), a body of the European Union. The document discusses several challenges facing the healthcare sector in Europe, including population aging, challenges for the pharmaceutical industry, obstacles for the medical technology industry, and issues with investments in prevention and primary care. It describes the role of EIT and Knowledge and Innovation Communities (KICs) in contributing to European competitiveness and innovation in healthcare. EIT Health aims to close the innovation gap through partnerships, accelerating projects, educating professionals, and focusing on areas like prevention and empowering patients.
The document describes CIMIT's CRAASH program which helps healthcare innovators commercialize their technologies. CRAASH provides teams with mentors experienced in medical technology entrepreneurship to guide them through customer discovery and developing a business model. Over the course of the program, teams interview stakeholders, develop marketing strategies, and present their progress weekly. Most teams discover their solution may not be viable or require changes, but about 1/3 accelerate their path to market. Nearly all participating teams obtain funding within a year to further develop their solutions. The goal is to help innovators successfully navigate challenges of commercializing healthcare technologies.
Presentation of CRAASH Barcelona, the new project of Biocat (Moebio Barcelona). The initiative is a 12-week program that helps European research teams launch successful device, diagnostic and e-/digital health innovations to improve health and patient care.
Toby Reid, Managing Director at BioCity Scotland, was the keynote speaker of the Graduation Cerimony of d·HEALTH Barcelona 2017.
BioCity is UK's largest bioscience incubation centre. Over 200 companies are based in a BioCity Group business incubator, with a 91% survival rate of companies.
The document summarizes Biocat's programs that aim to accelerate healthcare innovation and entrepreneurship in Catalonia. It describes two flagship programs - d·HEALTH Barcelona, a 9-month fellowship program that transforms clinical needs into solutions, and CRAASH, a new 10-week program helping early-stage projects. It provides details on the programs' structure, partners, successes and how organizations can collaborate. The goal is to dynamize stakeholders in the region and help technologies address real-world healthcare problems.
Moebio is he talent development initiative of Biocat to accelerate healthcare entrepreneurship.
Design Health Barcelona (d·HEALTH Barcelona) Is the full-time program of MOEBIO, inspired and modeled in the prestigiousStanford University's Biodesign Fellowshipthat seeks to train a team of fellows in the process of biodesign to develop innovative solutions.
Presentation of Mehrdad Hariri (Canadian Science Policy Centre (CPSC), CEO & President) at the Forum of the BioRegion of Catalonia, organized by Biocat.
Presentation of Zayna Khayat (MaRS Discovery District, Health System Innovation; MaRS EXCITE) at the Forum of the BioRegion of Catalonia, organized by Biocat.
Presentation of Susan Bannister (Massachusetts Life Sciences Center, Former President and CEO) at the Forum of the BioRegion of Catalonia, organized by Biocat.
This document discusses the evolution of healthcare and opportunities in digital health. It notes that healthcare is transitioning from a data poor to data rich science due to genomics, data science, mobile devices, and personalized medicine. This represents a shift from herd to personalized medicine. The document also discusses the growth of digital health funding and deals, increasing traction through FDA approvals and partnerships, and outlines a portfolio of digital health investment opportunities.
Presentation of Simon Howell (Founding Non-Executive Director of MedCity and Guy’s Campus Dean at King’s College London King’s College London) at the Forum of the BioRegion of Catalonia, organized by Biocat.
The document provides an overview of the life sciences and healthcare sector in Catalonia's "BioRegion". It summarizes that the sector contributes 7.3% to Catalonia's GDP and includes over 1,200 companies, mainly in biotech, pharma, medtech, and digital health. Investment in startups has grown steadily over the past five years to a record €120 million in 2020. The BioRegion has strong science and technology assets, including research centers, universities, and large infrastructures conducting cutting-edge research. Future challenges include improving technology transfer, attracting and developing talent, increasing investment, and ensuring a sustainable public health system.
Biocat is the institution that brings together the life sciences and healthcare innovation community in Catalonia.
Created in 2006 at the behest of the Government of Catalonia, Biocat’s mission is to maximize the economic and social impact of the life sciences and healthcare innovation of the BioRegion.
Biocat focuses its strategy on different key points:
- Raising awareness and promoting the ecosystem, creating tools and strategies for improving the knowledge of the Catalan healthcare sector and increasing its projection both at home and abroad, with the aim of positioning the BioRegion as an international reference.
- Providing innovative training and developing talent, by designing and executing programs and initiatives to improve talent and entrepreneurship considered essential factors for the growth of the sector.
- Accelerating technology transfer and business growth by supporting and carrying out activities for increasing the value of the sector, placing special emphasis on the added value of research, knowledge and technology transfer, internationalization and access to capital.
This document discusses Catalonia's growing innovation hub status in Europe. It notes that in 2018, 17 multinationals announced new innovation set-ups in Catalonia. It also summarizes that Barcelona is ranked 34th worldwide and 8th in Europe for science output. Furthermore, the document highlights that Catalonia is currently one of the leading scientific hubs in Europe based on metrics like ERC grants and publications in Nature and Science.
Biocat has experience in accelerating healthcare projects and developing talent since 2008. In 10 years, Biocat has invested over €11 million, distributed in 300 programs attended by more than 2,300 students. By leveraging its expert, industry experienced, staff and extended network, Biocat has successfully accelerated 96 life sciences projects that generated 300 new job positions, increased the rate of successful commercialization and reduced the time to next phase. In 2013, in order to increase the impact of these strategic activities. Biocat launched Moebio, a new initiative that brings together diferent training programs to accelerate entrepreneurship and innovation in healthcare, that counts with the support of EIT Health. Moebio is ranked as one of the top accelerators in Europe according to rankings by Digitalhealth.careers, Mobile World Capital, Tech EU and HealthStartup.
Design Health Barcelona (d·HEALTH Barcelona) is a 9-month postgraduate program to develop entrepreneurs and future leaders in healthcare innovation. The course, based on the prestigious Stanford University's Biodesign Fellowship, has a needs-driven innovation focus and it guides multidisciplinary groups of students through a full cycle of innovation, from needs identification to designing and prototyping a viable solution, as well as searching for funding.
www.moebio.org
The document summarizes a report on innovation in the Catalan life sciences and healthcare sector. It finds that the sector contributes over €31 billion annually to the Catalan GDP and employs over 223,000 people. The number of life sciences companies in Catalonia grew from 968 in 2008 to over 1,000 currently, with one new company forming per week on average. Private investment in Catalan life sciences startups has increased significantly in recent years, reaching over €100 million in the first half of 2018. The report sets a vision of continuing to build on Catalonia's strengths in research and private funding to become one of the top 3 most innovative life sciences hubs in Europe by 2025.
Keynote conference during the Biocat Report 2017, by Dr. Daria Tataj, Founder of a strategy firm Tataj Innovation, and Chairwoman of the RISE High-Level Advisors to Carlos Moedas, European Commissioner for Research, Science and Innovation
Panel discussion: Being a successful healthcare entrepreneur: lessons from Boston to Barcelona, with numerous experts from CIMIT, Boston, in economics, development and strategic planning of medical devices; in prototypes and patents and founders of several startups.
EIT Health is supported by the European Institute of Innovation and Technology (EIT), a body of the European Union. The document discusses several challenges facing the healthcare sector in Europe, including population aging, challenges for the pharmaceutical industry, obstacles for the medical technology industry, and issues with investments in prevention and primary care. It describes the role of EIT and Knowledge and Innovation Communities (KICs) in contributing to European competitiveness and innovation in healthcare. EIT Health aims to close the innovation gap through partnerships, accelerating projects, educating professionals, and focusing on areas like prevention and empowering patients.
The document describes CIMIT's CRAASH program which helps healthcare innovators commercialize their technologies. CRAASH provides teams with mentors experienced in medical technology entrepreneurship to guide them through customer discovery and developing a business model. Over the course of the program, teams interview stakeholders, develop marketing strategies, and present their progress weekly. Most teams discover their solution may not be viable or require changes, but about 1/3 accelerate their path to market. Nearly all participating teams obtain funding within a year to further develop their solutions. The goal is to help innovators successfully navigate challenges of commercializing healthcare technologies.
Presentation of CRAASH Barcelona, the new project of Biocat (Moebio Barcelona). The initiative is a 12-week program that helps European research teams launch successful device, diagnostic and e-/digital health innovations to improve health and patient care.
Toby Reid, Managing Director at BioCity Scotland, was the keynote speaker of the Graduation Cerimony of d·HEALTH Barcelona 2017.
BioCity is UK's largest bioscience incubation centre. Over 200 companies are based in a BioCity Group business incubator, with a 91% survival rate of companies.
The document summarizes Biocat's programs that aim to accelerate healthcare innovation and entrepreneurship in Catalonia. It describes two flagship programs - d·HEALTH Barcelona, a 9-month fellowship program that transforms clinical needs into solutions, and CRAASH, a new 10-week program helping early-stage projects. It provides details on the programs' structure, partners, successes and how organizations can collaborate. The goal is to dynamize stakeholders in the region and help technologies address real-world healthcare problems.
Moebio is he talent development initiative of Biocat to accelerate healthcare entrepreneurship.
Design Health Barcelona (d·HEALTH Barcelona) Is the full-time program of MOEBIO, inspired and modeled in the prestigiousStanford University's Biodesign Fellowshipthat seeks to train a team of fellows in the process of biodesign to develop innovative solutions.
Presentation of Mehrdad Hariri (Canadian Science Policy Centre (CPSC), CEO & President) at the Forum of the BioRegion of Catalonia, organized by Biocat.
Presentation of Zayna Khayat (MaRS Discovery District, Health System Innovation; MaRS EXCITE) at the Forum of the BioRegion of Catalonia, organized by Biocat.
Presentation of Susan Bannister (Massachusetts Life Sciences Center, Former President and CEO) at the Forum of the BioRegion of Catalonia, organized by Biocat.
This document discusses the evolution of healthcare and opportunities in digital health. It notes that healthcare is transitioning from a data poor to data rich science due to genomics, data science, mobile devices, and personalized medicine. This represents a shift from herd to personalized medicine. The document also discusses the growth of digital health funding and deals, increasing traction through FDA approvals and partnerships, and outlines a portfolio of digital health investment opportunities.
Presentation of Simon Howell (Founding Non-Executive Director of MedCity and Guy’s Campus Dean at King’s College London King’s College London) at the Forum of the BioRegion of Catalonia, organized by Biocat.
2. BIOMATERIALS
A Biomaterial is a non viable material used in a medicalA Biomaterial is a non viable material used in a medical
device, intented to interact with biological systems
D F Williams 1987D.F. Williams 1987
SER EL MÉS AMPLI POSSIBLE
1
4. BIOMATERIALS
NOU PARADIGMANOU PARADIGMA
DE MATERIALS DE SUPORT A MATERIALS
INTEL LIGENTSINTEL.LIGENTS
BASTIDES (SCAFFOLDS) INTEL.LIGENTS
3
BASTIDES (SCAFFOLDS) INTEL.LIGENTS
5. BIOMATERIALS
EXEMPLES DE BIOMATERIALS CLÀSSICSEXEMPLES DE BIOMATERIALS CLÀSSICS
Implant de titani de Titani Implant de titani de Titani
Pròtesi de maluc
Vàlvula cardíaca
Lent de Contacte
4
6. BIOMIMETISME
BIOMIMETISME o BIOMIMETIC
l l d lImitar les arquitectures i les estrategies de la NATURA
AMBIENTS CEL LULARS BIOMIMETICS
b d ®
Picture from Tracy E. Anderson
(Imaging Center College of
Biological Sciences St. Paul, MN,
USA)
1 m 1 m
Colàgen natural Peptids
Sieminski, A. L., et al., Cell
Biochemisry & Biophysics,
49, 73-83, 2007
1 m 1 m
AMBIENTS CEL.LULARS BIOMIMETICS
bardana Velcro®Colàgen natural Peptids
autoensamblbles
(RAD 16-I)
5
7. ÀMBIENTS CEL:LULARS BIOMIMÈTICS
proteins of the extracellular matrix
mech
mechmech
mech
loading tension shear torsion
matrix deformation
proteins of the extracellular matrix
soluble factors
receptor - ligand recognition
signaling
signaling
mechanical
mechanical
sisi
signaling
signaling
mechanical
mechanical
sisi
cell deformation
ll l
intracellular signals cascade
ll l
BIOMIMETICBIOMIMETIC
ENVIRONMENTENVIRONMENT
chemical
chemical
signaling
signaling
BIOMIMETICBIOMIMETIC
ENVIRONMENTENVIRONMENT
chemical
chemical
signaling
signaling
cellular responsecellular response
physicalphysical propertiespropertiesphysicalphysical propertiesproperties
• micro- and nanostructure
• matrix stiffness
6
http://www.scienceclarified.com/R
o-Sp/Skeletal-System.html
100 – 300 m
Alberts, B., Molecular
Biology of the Cell (2004)
8. BIOMATERIALS
Requeriments per a un recobrimentRequeriments per a un recobriment
polimeric orgànicpolimeric orgànicp gp g
Ionització suauIonització suauEstructura repetible iEstructura repetible i Ionització suauIonització suau
conegudaconeguda
Unir covalentmentUnir covalentment
biomol.lèculesbiomol.lècules
Senyalització QuímicaSenyalització Química
CopolimeritzacióCopolimeritzacióControl de la duresaControl de la duresa
Control del gruix i ús deControl del gruix i ús deMicro andMicro and
7
màscaresmàscaresnanoestructuraciónanoestructuració
12. BIODEGRADACIÓ QUÍMICA
Tipus d’enllaç Químic Tipus d enllaç Químic
pH
Temperatura ?p
Composició
Water uptake (hidrofilia)
ÓMINERALIZACIÓ
11
17. OBJECTIUS
Desenvolupament d’un nou materialDesenvolupament d un nou material.
Adaptabiliat
Propietats mecàniques
Alliberament de calciAlliberament de calci
Biocompatible
BiodegradableBiodegradable
16
18. COMPONENTS
Di idDiacid
Amine“HARD”
Estructura patentada.
Biodegradació
controlada en funcióAmine
Diols
“HARD” controlada en funció
ingredients.
Duresa controlableDiols
P l l
Duresa controlable
per a qualsevol ús
mèdic.
Fà il dPolyols“SOFT
”
Fàcil de procesar
Comercialitzable en
diferents
HidroxyapatiteLoad
diferents
conformacions
17
20. COMPONENTS
Cuando se aplica un
esforç de cisalla elç
material comença a fluir,
degut a la desaparició de
les forces intermolecularsles forces intermoleculars
en el segment
En absència de l’esforç de
i ll t l t tcisalla torna al seu estat
original.
Canviant la composcicióp
canvien les interaccions I
la duresa
19
24. GPC
Baixa
Polidispersivitat.
C t l d lControl del pes
molecular amb el
control de les
condicions de
reacció
Mn Mw Polydispersity
T8T1 2938 6666 2,269
T8T2 3396 6660 1,961
T8T5 3142 6849 2,180
T8T8 3700 7111 1,922
23
25. BIODEGRADABILITAT
In Vivo tests (calvary defects)
Pasta (sense Hidroxiapatita)
Nivell macroscopic: no complicacions
No hi ha inflamació.
Passa el test de toxicitat aguda
Completament reabsorbit després de 12
setmanes
Ion Tcacencu, Mikael Wendel, J Mater Sci: Mater Med, ,
24
27. DESENVOLUPAMENT DE NEGOCI
Creació d’una Spin OffCreació d una Spin Off.
Protecció de la Tecnologia IP
Preparació d’un Pla de Negoci
Desenvolupament de la tecnologiaDesenvolupament de la tecnologia
Cerca de finançament
Desenvolupament del NegociDesenvolupament del Negoci
26
28. DESENVOLUPAMENT DE NEGOCI
Creació d’una Spin OffCreació d una Spin Off.
Protecció de la Tecnologia IP
Preparació d’un Pla de Negoci
Desenvolupament de la tecnologiaDesenvolupament de la tecnologia
Cerca de finançament
Desenvolupament del NegociDesenvolupament del Negoci
27
29. DESENVOLUPAMENT DE NEGOCI
Creació d’una Spin OffCreació d una Spin Off.
Protecció de la Tecnologia IP
Preparació d’un Pla de Negoci
Desenvolupament de la tecnologiaDesenvolupament de la tecnologia
Cerca de finançament
Desenvolupament del NegociDesenvolupament del Negoci
28
30. DESENVOLUPAMENT DE NEGOCI
Creació d’una Spin OffCreació d una Spin Off.
Protecció de la Tecnologia IP
Preparació d’un Pla de Negoci
Desenvolupament de la tecnologiaDesenvolupament de la tecnologia
Cerca de finançament
Desenvolupament del NegociDesenvolupament del Negoci
29
31. DESENVOLUPAMENT DE NEGOCI
Creació d’una Spin OffCreació d una Spin Off.
Protecció de la Tecnologia IP
Preparació d’un Pla de Negoci
Desenvolupament de la tecnologiaDesenvolupament de la tecnologia
Cerca de finançament
Desenvolupament del NegociDesenvolupament del Negoci
30
32. DESENVOLUPAMENT DE NEGOCI
Creació d’una Spin OffCreació d una Spin Off.
Protecció de la Tecnologia IP
Preparació d’un Pla de Negoci
Desenvolupament de la tecnologiaDesenvolupament de la tecnologia
Cerca de finançament
Desenvolupament del NegociDesenvolupament del Negoci
31
33. Eduard Diviu Terradas
SAGETIS BIOTECH, SL
C/Llacuna 162, 08018 Barcelona
T +34 933 097 169T +34 933 097 169
ediviu@sagetis-biotech.com
Contact
Dr. Salvador Borrós Gómez
SAGETIS BIOTECH, SL
C/Llacuna 162, 08018 Barcelona
T 34 933 097 169T +34 933 097 169
sborros@sagetis-biotech.com
David Horna Tomás
SAGETIS BIOTECH, SL
C/Llacuna 162, 08018 Barcelona
T +34 933 097 169
dhorna@sagetis-biotech.com